Asparaginase Erwinia chrysanthemi Brand Name– Erwinaze
What is Asparaginase Erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi is an asparagine specific enzyme indicated in combination with multi-agent chemotherapy for the treatment of patients aged 1 year and older with acute lymphoblastic leukemia who have developed hypersensitivity to Escherichia (E.) coli-derived asparaginase.
Asparaginase Erwinia chrysanthemi may replace a dose of the modified version of E. coli L-asparaginase (pegaspargase) or a dose of native E. coli asparaginase (L-Asparaginase).
Asparaginase Erwinia chrysanthemi is contraindicated in patients with a history of serious hypersensitivity reactions to any component of the product or who have had serious pancreatitis, thrombosis, or bleeding events with prior L-asparaginase therapy.
Indications
- acute lymphocytic leukemia (ALL)
For the treatment of acute lymphocytic leukemia (ALL) in combination with other chemotherapeutic agents in patients who have developed hypersensitivity to E. coli-derived asparaginase
Side Effects
- abdominal pain
- anaphylactic shock
- anaphylactoid reactions
- antibody formation
- bleeding
- diarrhea
- disseminated intravascular coagulation (DIC)
- elevated hepatic enzymes
- fever
- headache
- hyperammonemia
- hyperbilirubinemia
- hyperglycemia
- injection site reaction
- nausea
- pancreatitis
- seizures
- thrombosis
- urticaria
- vomiting
Monitoring Parameters
- blood glucose
- pregnancy testing
Contraindications
- bleeding
- breast-feeding
- children
- contraception requirements
- diabetes mellitus
- hepatic disease
- hyperglycemia
- infants
- pancreatitis
- pregnancy
- pregnancy testing
- reproductive risk
- thromboembolic disease
Interactions
- Antithymocyte Globulin
- Carbamazepine
- Corticosteroids
- Cytarabine, ARA-C
- Methotrexate
- Thyroid hormones
- Vincristine
- Vincristine Liposomal
- Zonisamide
